Nurses have a responsibility to understand the unique needs of the LGBTQ+ community in order to provide quality, unbiased, and holistic care. Continued professional growth in this area will allow patients to feel safe and to be an active participant in their care.

The NCCN Guidelines for Systemic Mastocytosis provide evidence- and consensus-based recommendations for the diagnosis and comprehensive care of patients with systemic mastocytosis. The multidisciplinary panel of experts convenes at least once a year to review requested changes to the guidelines from both internal and external entities as well as to discuss data on existing and new therapies. These NCCN Guidelines Insights focus on some of the recent updates to the guidelines.

Recent studies delineating molecular alterations in pancreatic cancer and germline alterations in individuals with pancreatic cancer highlight the need to understand the changing landscape of clinical tools available for diagnosing and treating this cancer effectively.

For many years, platinum plus etoposide regimens had been recommended for patients with extensive stage small cell lung cancer (SCLC); however, the preferred regimens for extensive stage SCLC now include immune checkpoint inhibitors, either atezolizumab or durvalumab, plus platinum plus etoposide.